Unmasking viral sequences by metagenomic next-generation sequencing in adult human blood samples during steroid-refractory/dependent graft-versus-host disease

Table 1 Patients’ characteristics (25 allo-HSCT patients)

	Total
	n = 25
Demographics
Sex (male), n (%)	16 (64.0)
Age, median (IQR)	58.0 (25.0)
Allo-HSCT considered in the analysis, n (%)
First	23 (92.0)
Second	2 (8.0)
Transplant source, n (%)
Bone marrow	5 (20)
Peripheral blood cells	20 (80)
Underlying disease, n (%)
Acute myeloid leukemia	10 (40.0)
Lymphoid malignancy	6 (24.0)
MDS/MDPS	3 (12.0)
Acute lymphoid leukemia	2 (8.0)
Other^a	4 (16.0)
Risk score, n (%)
Low	0 (0)
Intermediate	18 (72.0)
High	7 (28.0)
Donor sex, M, n (%)	7 (28.0)
Donor age, median (IQR)	36 (16.5)
Donor match, n (%)
Donor-related	10 (40.0)
CMV donor/recipient constellation, n (%)
+/+	12 (48.0)
−/+	1 (4.0)
+/−	7 (28.0)
−/−	5 (20.0)
CMV prophylaxis, n (%)	1 (4.0)
Conditioning, n (%)
Myeloablative conditioning	5 (20.0)
GvHD prophylaxis, n (%)
Calcineurin inhibitor	24 (96.0)
Mycophenolate mofetil	17 (68.0)
Methotrexate	7 (28.0)
GvHD organ, n (%)
Digestive tract	17 (68.0)
Skin	15 (60.0)
Mouth	4 (16.0)
Liver	7 (28.0)
Lung	5 (20.0)
Eyes	2 (8.0)
Musculoskeletal	1 (4.0)
GvHD grade or severity, n (%)
Grade
2	9 (36.0)
3	3 (12.0)
4	6 (24.0)
Moderate	6 (24.0)
Severe	7 (28.0)
GvHD treatment, n (%)
Corticosteroids	24 (96.0)
Ruxolitinib	22 (88.0)
Calcineurin inhibitor	21 (84.0)
Mycophenolate mofetil	12 (48.0)
Photopheresis	12 (48.0)
Budenoside	5 (20.0)
Sirolimus	3 (12.0)
Tocilizumab	2 (8.0)
Other^b	6 (24.0)
Death, n (%)	15 (60.0)
Median delay from allo-HSCT, months (IQR)	11.2 (15.8)

One patient could have multiple GvHD prophylaxis and treatment, multiple organs with GvHD and multiple grades of severity. CMV prophylaxis: one patient (patient Ge24) received letermovir during the period of intensive steroid treatment or second-line GvHD therapy. GvHD grade refers to acute GvHD, GvHD severity refers to chronic GvHD. In two patients, there was no information on grade/severity. Only organs with grade GvHD ≥ 2 or severity ≥ moderate are reported
Abbreviations: IQR interquartile range, allo-HSCT allogeneic hematopoietic stem cell transplantation, MDS/MDPS myelodysplasic syndrome/myelodysplasic proliferative syndrome, ATG anti-thymocyte globulin
^aOther includes: multiple myeloma (n = 2), chronic myeloid leukemia (n = 1) and mixed acute leukemia (n = 1)
^bOther includes: azithromycine, montelukast, prolastin, vedolisumab, nilotinib, basilixumab, ibrutinib, and/or methotrexate

ISSN: 2049-2618